A Medicine Marketing Company
Closing the distance between a medicine that works and a patient who is taking it.
Our industry spends more every year to reach prescribers — and reaches fewer of them.
The doors are shutting. Not because clinicians stopped caring about medicine, but because they stopped wanting to hear about it from the company that makes it.
We are not the rep. We are not the brand. We are not the company that makes the medicine. That distance is the asset.
SharePath closes the blind spots our clients cannot reach themselves.
We exist to help great medicines reach the patients who need them.
Medical innovation has never moved faster. Yet many important therapies remain misunderstood, underutilized, or overlooked.
Our mission is simple: to help healthcare professionals discover, evaluate, and understand the therapies changing patient lives.
Three platforms. One ecosystem.
Health-Scripts helps healthcare professionals connect through peer-led education, clinical discussion, and prescribing support.
Visit Health-Scripts →Point of Prompt helps life sciences organizations understand, measure, and influence how AI platforms represent their medicines.
Visit Point of Prompt →The NP/PA Institute helps life sciences brands understand, measure, and activate the Advanced Practice Provider ecosystem shaping today's prescribing decisions.
Explore the Institute →Between a medicine that works and a patient who is taking it, there is a distance.
Closing that distance is the whole of our business.
It is measured in time — days, weeks, sometimes years — and it is made of gaps. A prescriber who never hears. A patient who never learns the option exists. A prescription written but never filled. Every one of those gaps is a person waiting longer than they should for something that already exists to help them.
There are three blind spots where this happens. All three are growing.
The access gap
More prescribers are restricted, no-see, or simply unreceptive to direct promotion. The industry's answer has been to push harder against the same closed door. Ours is to already be in the room — 650,000 verified clinicians, reached outside any single company's ecosystem, through peers instead of reps. Not a workaround. A better front door.
The AI gap
Prescribers now ask machines what they used to ask journals and colleagues. So do patients — about the medicine they were just prescribed, the one they saw an ad for, the one they are afraid to start. Those answers are being formed right now, about every brand in the market, in rooms no one from pharma is standing in. Unmanaged. Unmonitored. Unmeasured.
The prescriber gap
Nurse practitioners and physician assistants write a fast-growing share of the prescriptions in this country, and the commercial model was built for physicians. Treating the fastest-growing prescriber segment as an afterthought is not a strategy — it is a quiet decision about whose patients receive the best-informed care.
Each of these is a place where the influence is real and the visibility is not.
And here is why we can go where our clients cannot: we are not the rep. We are not the brand. We are not the company that makes the medicine.
That distance is not a limitation we work around. It is the asset. Clinicians open doors to independent voices that they close to commercial ones. Patients trust what they did not have to be sold. Our independence is what earns the access — and what makes the access worth having.
Our work is the bridge. That is the path — and that is what we share.
With extensive experience in pharmaceutical commercialization, Jeff founded SharePath around a simple belief:
Great medicines deserve a trusted path into clinical conversation.
Today SharePath supports life sciences organizations through platforms that connect healthcare professionals, commercial teams, and emerging AI ecosystems.
The blind spots are still growing.
The prescribing journey is evolving rapidly. Clinical conversations increasingly occur across professional networks, digital communities, and artificial intelligence platforms.
SharePath builds the platforms that reach into those conversations — independently, credibly, and on the clinician’s terms.
Start a Conversation